Aarey Drugs & Pharmaceuticals financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹44.6cr−56.3% on Q1 FY26
Net profit
₹1.0cr−25.4% on Q1 FY26
EBITDA margin
3.0%+1.3 pts on Q1 FY26
EPS
₹0.36−25.0% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue44.6102−56.3%
EBITDA1.31.7−22.2%
EBITDA margin3.0%1.7%+1.3 pts
Profit before tax0.51.7−70.2%
Net profit1.01.4−25.4%
EPS₹0.36₹0.48−25.0%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹44.6 crNet profit₹1.0 crNet margin2.3%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
307————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.41.41.51.60.7
50.050.034.931.437.7
356————
41547247439662.5
—−0.4%+19.8%+533.3%—
6.87.22.34.51.5
1.6%1.5%0.5%1.1%2.5%
3.64.30.32.80.8
4.24.04.04.70.5
1.0%0.8%0.9%1.2%0.8%
₹1.47₹1.39₹1.41₹1.65₹0.17
—−1.4%−14.1%+847.1%—
—10.19.77.9−39.1
—−12.40.00.0−1.0
−2.3−2.39.77.9−40.1
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

AAREYDRUGS₹108.05

Aarey Drugs & Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersNECLIFENATCAPSUQMEDICAMEQMEDICOBALPHARMAALPAKREBSBIOHALEOSLABSMcap ₹307 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————307.4
- Cash, Equiv & ST Investments0.71.61.51.41.4
+ Total Debt37.731.434.950.050.0
Enterprise Value————356.0
Revenue62.5395.6473.9472.3414.7
Growth %, YoY—+533.3+19.8-0.4—
EBITDA1.54.52.37.26.8
Margin %2.451.130.481.521.64
EBIT0.82.80.34.33.6
Net Income0.54.74.04.04.2
Margin %0.791.180.850.841.01
EPS, Adj (current shares)0.171.651.411.391.47
Growth %, YoY—+847.1-14.1-1.4—
Cash from Operations-39.17.99.710.1—
Capital Expenditures-1.0-0.0-0.0-12.4—
Free Cash Flow-40.17.99.7-2.3-2.3
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Aarey Drugs & Pharmaceuticals financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Aarey Drugs & Pharmaceuticals (NSE: AAREYDRUGS) had a market capitalisation of ₹315 crore at the 29 October 2026 close (₹110.84 a share), a PE ratio of 75.6 on the last four quarters' profit and a price-to-book ratio of 2.10. In FY26 its consolidated net profit was ₹4 crore on revenue of ₹472 crore; in Q1 FY27 (April–June 2026) it was ₹1 crore, down 25.4% year on year. Its debt-to-equity ratio was 0.33 on 31 March 2026. Promoters held 41.45% of the shares on 30 September 2026.

Share price used
₹110.84 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Aarey Drugs & Pharmaceuticals at a glance · consolidated

Market cap
₹315 Crat ₹110.84 · 29 Oct close
PE ratio (last 4 quarters)
75.679.5 on FY26 profit
Price to book (PB)
2.10book value ₹52.86 a share
ROE (FY26)
2.8%−0.2 pts vs FY25ROCE 2.9%
Debt to equity
0.33net debt ₹48.6 Cr
Promoter holding
41.45%+3.7 pts vs 30 Jun 202630 September 2026
Net worth
₹150 Cr+8.6% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹2.3 Cr
EPS (FY26)
₹1.39

Questions

What is the Aarey Drugs & Pharmaceuticals PE ratio today?

Aarey Drugs & Pharmaceuticals' PE ratio is 75.6 at the 29 October 2026 close (₹110.84 a share): a market capitalisation of ₹315 crore divided by consolidated net profit of ₹4.2 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹4 crore) it is 79.5.

What is the Aarey Drugs & Pharmaceuticals PB ratio (price to book value)?

Aarey Drugs & Pharmaceuticals' price-to-book (PB) ratio is 2.10 at the 29 October 2026 close: a market capitalisation of ₹315 crore divided by shareholders' equity (book value) of ₹150 crore on 31 March 2026. That is a book value of ₹52.86 per share against a share price of ₹110.84.

Is Aarey Drugs & Pharmaceuticals debt free?

No. Aarey Drugs & Pharmaceuticals had borrowings of ₹50 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.33. Its cash and current investments were ₹1.4 crore, so its net debt was ₹48.6 crore.

What is the Aarey Drugs & Pharmaceuticals market cap?

Aarey Drugs & Pharmaceuticals' market capitalisation was ₹315 crore at the 29 October 2026 close: 2.85 crore shares at ₹110.84 each.

What is the Aarey Drugs & Pharmaceuticals debt to equity ratio?

Aarey Drugs & Pharmaceuticals' debt-to-equity ratio was 0.33 on 31 March 2026: borrowings of ₹50 crore against total equity of ₹150 crore. A year earlier, on 31 March 2025, it was 0.25.

What is the Aarey Drugs & Pharmaceuticals book value per share?

Aarey Drugs & Pharmaceuticals' book value per share was ₹52.86 on 31 March 2026: shareholders' equity of ₹150 crore divided by the 2.85 crore shares in issue. The share price at the 29 October 2026 close was ₹110.84.

What is the Aarey Drugs & Pharmaceuticals net worth?

Aarey Drugs & Pharmaceuticals' net worth — shareholders' equity in its consolidated balance sheet — was ₹150 crore on 31 March 2026, up 8.6% from ₹138 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹315 crore at the 29 October 2026 close.

What is the Aarey Drugs & Pharmaceuticals ROE and ROCE?

In FY26, Aarey Drugs & Pharmaceuticals' return on equity (ROE) was 2.8% and its return on capital employed (ROCE) was 2.9%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 3.0% and ROCE 0.2%.

What is the Aarey Drugs & Pharmaceuticals shareholding pattern?

On 30 September 2026, Aarey Drugs & Pharmaceuticals' shares were held by promoters 41.45%, foreign portfolio investors (FII/FPI) 4.27%, domestic institutions (DII) 1.44% and retail and other non-institutional investors 52.83%. Over the year, FII holding was up 3.14 percentage points from 1.13%.

What is the Aarey Drugs & Pharmaceuticals EPS?

Aarey Drugs & Pharmaceuticals' basic earnings per share (EPS) were ₹1.39 in FY26. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹1.83.

What is the Aarey Drugs & Pharmaceuticals promoter holding?

Promoters held 41.45% of Aarey Drugs & Pharmaceuticals on 30 September 2026, up 3.74 percentage points from 37.71% the previous quarter and down 3.35 percentage points from 44.80% a year earlier, according to the shareholding pattern filed with NSE.

When are the Aarey Drugs & Pharmaceuticals next results?

Aarey Drugs & Pharmaceuticals has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

What is the Aarey Drugs & Pharmaceuticals free cash flow?

In FY26, Aarey Drugs & Pharmaceuticals generated ₹10.1 crore of cash from operations and spent ₹12.4 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹2.3 crore. In FY25 it was ₹9.7 crore.

What are the Aarey Drugs & Pharmaceuticals latest quarterly results?

Aarey Drugs & Pharmaceuticals' latest results are for Q1 FY27 (April–June 2026), filed on 14 August 2026: consolidated net profit ₹1 crore, down 25.4% from ₹1.4 crore in Q1 FY26; revenue from operations ₹44.6 crore, down 56.3% year on year.

What is the Aarey Drugs & Pharmaceuticals revenue and profit in FY26?

In FY26 (April 2025–March 2026), Aarey Drugs & Pharmaceuticals' consolidated net profit was ₹4 crore, down 1.4% from ₹4 crore in FY25, on revenue from operations of ₹472 crore (down 0.4%). Over three years, from FY23, net profit was up 702.3%.

How does Aarey Drugs & Pharmaceuticals compare with its peers?

On FY26 consolidated figures, against Nectar Lifesciences, Natural Capsules and Medicamen Biotech: Aarey Drugs & Pharmaceuticals' return on equity of 2.8% is the second highest of the four (Nectar Lifesciences −38.1%, Natural Capsules −7.5%, Medicamen Biotech 4.0%; peer average −13.9%).

Aarey Drugs & Pharmaceuticals vs Nectar Lifesciences: how do they compare?

In FY26, Aarey Drugs & Pharmaceuticals earned net profit of ₹4 crore on revenue of ₹472 crore, against ₹293 crore on ₹0 lakh for Nectar Lifesciences. At the 29 October 2026 close, Aarey Drugs & Pharmaceuticals' market capitalisation was ₹315 crore against ₹201 crore for Nectar Lifesciences.

Where do these Aarey Drugs & Pharmaceuticals figures come from?

From Aarey Drugs & Pharmaceuticals' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.